Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2005

01-04-2005 | Review

Update on inflammatory breast cancer

Authors: Florence Lerebours, Ivan Bieche, Rosette Lidereau

Published in: Breast Cancer Research | Issue 2/2005

Login to get access

Abstract

Inflammatory breast cancer (IBC) is both the least frequent and the most severe form of epithelial breast cancer. The diagnosis is based on clinical inflammatory signs and is reinforced by pathological findings. Significant progress has been made in the management of IBC in the past 20 years. Yet survival among IBC patients is still only one-half that among patients with non-IBC. Identification of the molecular determinants of IBC would probably lead to more specific treatments and to improved survival. In the present article we review recent advances in the molecular pathogenesis of IBC. A more comprehensive view will probably be obtained by pan-genomic analysis of human IBC samples, and by functional in vitro and in vivo assays. These approaches may offer better patient outcome in the near future.
Literature
1.
Jaiyesimi IA, Buzdar AU, Hortobagyi G: Inflammatory breast cancer: a review. J Clin Oncol. 1992, 10: 1014-1024.CrossRefPubMed
2.
Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD: Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer. 1998, 82: 2366-2372.CrossRefPubMed
3.
Cristofanilli M, Buzdar AU, Hortobagyi GN: Update on the management of inflammatory breast cancer. Oncologist. 2003, 8: 141-148. 10.1634/theoncologist.8-2-141.CrossRefPubMed
4.
Fleming RY, Asmar L, Buzdar AU, McNeese MD, Ames C, Ross MI, Singletary SE: Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol. 1997, 4: 452-461.CrossRefPubMed
5.
Arun B, Slack R, Gehan E, Spitzer T, Meehan KR: Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Cancer. 1999, 85: 93-99.CrossRefPubMed
6.
Bertucci F, Tarpin C, Charafe-Jauffret E, Bardou VJ, Braud AC, Tallet A, Gravis G, Viret F, Goncalves A, Houvenaeghel G, et al: Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment. Bone Marrow Transplant. 2004, 33: 913-920. 10.1038/sj.bmt.1704458.CrossRefPubMed
7.
Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R, Shibata S, Chu P, Forman S, Lim D, et al: Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol. 2004, 22: 1839-1848. 10.1200/JCO.2004.10.147.CrossRefPubMed
8.
Anderson WF, Chu KC, Chang S: Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?. J Clin Oncol. 2003, 21: 2254-2259. 10.1200/JCO.2003.07.082.CrossRefPubMed
9.
Kleer CG, van Golen KL, Merajver SD: Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res. 2000, 2: 423-429. 10.1186/bcr89.CrossRefPubMedPubMedCentral
10.
Paradiso A, Tommasi S, Brandi M, Marzullo F, Simone G, Lorusso V, Mangia A, De Lena M: Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer. 1989, 64: 1922-1927.CrossRefPubMed
11.
Brenner B, Siris N, Rakowsky E, Fenig E, Sulkes A, Lurie H: Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers. Br J Cancer. 2002, 87: 1404-1410. 10.1038/sj.bjc.6600616.CrossRefPubMedPubMedCentral
12.
Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hassoun J, Birnbaum D, et al: Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol. 2004, 202: 265-273. 10.1002/path.1515.CrossRefPubMed
13.
Henderson MA, McBride CM: Secondary inflammatory breast cancer: treatment options. South Med J. 1988, 81: 1512-1517.CrossRefPubMed
14.
Piera JM, Alonso MC, Ojeda MB, Biete A: Locally advanced breast cancer with inflammatory component: a clinical entity with a poor prognosis. Radiother Oncol. 1986, 7: 199-204.CrossRefPubMed
15.
Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, Van De Vijver M, MacGrogan G, Shepherd L, Amaral N, Duval C, Drijkoningen R, et al: Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?. Ann Oncol. 2003, 14: 406-413. 10.1093/annonc/mdg108.CrossRefPubMed
16.
Kleer CG, van Golen KL, Braun T, Merajver SD: Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol. 2001, 14: 458-464. 10.1038/modpathol.3880334.CrossRefPubMed
17.
Turpin E, Bieche I, Bertheau P, Plassa LF, Lerebours F, de Roquancourt A, Olivi M, Espie M, Marty M, Lidereau R, et al: Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene. 2002, 21: 7593-7597. 10.1038/sj.onc.1205932.CrossRefPubMed
18.
Bonnier P, Charpin C, Lejeune C, Romain S, Tubiana N, Beedassy B, Martin PM, Serment H, Piana L: Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition?. Int J Cancer. 1995, 62: 382-385.CrossRefPubMed
19.
Amparo RS, Angel CD, Ana LH, Antonio LC, Vicente MS, Carlos FM, Vicente GP: Inflammatory breast carcinoma: pathological or clinical entity?. Breast Cancer Res Treat. 2000, 64: 269-273. 10.1023/A:1026512722789.CrossRefPubMed
20.
Delarue JC, May-Levin F, Mouriesse H, Contesso G, Sancho-Garnier H: Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast. Br J Cancer. 1981, 44: 911-916.CrossRefPubMedPubMedCentral
21.
Aziz SA, Pervez S, Khan S, Kayani N, Azam SI, Rahbar MH: Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J. 2001, 7: 398-404. 10.1046/j.1524-4741.2001.07604.x.CrossRefPubMed
22.
Guerin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, Riou G: Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer. 1989, 43: 201-208.CrossRefPubMed
23.
Prost S, Le MG, Douc-Rasy S, Ahomadegbe JC, Spielmann M, Guerin M, Riou G: Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer. 1994, 58: 763-768.CrossRefPubMed
24.
Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996, 2: 811-814. 10.1038/nm0796-811.CrossRefPubMed
25.
Faille A, De Cremoux P, Extra JM, Linares G, Espie M, Bourstyn E, De Rocquancourt A, Giacchetti S, Marty M, Calvo F: p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer. 1994, 69: 1145-1150.CrossRefPubMedPubMedCentral
26.
Riou G, Le MG, Travagli JP, Levine AJ, Moll UM: Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst. 1993, 85: 1765-1767.CrossRefPubMed
27.
Moll UM, Riou G, Levine AJ: Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA. 1992, 89: 7262-7266.CrossRefPubMedPubMedCentral
28.
McCarthy NJ, Yang X, Linnoila IR, Merino MJ, Hewitt SM, Parr AL, Paik S, Steinberg SM, Hartmann DP, Mourali N, et al: Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res. 2002, 8: 3857-3862.PubMed
29.
Charpin C, Bonnier P, Khouzami A, Vacheret H, Andrac L, Lavaut MN, Allasia C, Piana L: Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/ neu, pS2, cathepsin, ER and PR. Anticancer Res. 1992, 12: 591-597.PubMed
30.
Van den Eynden GG, Van der Auwera I, Van Laere S, Colpaert CG, van Dam P, Merajver S, Kleer CG, Harris AL, Van Marck EA, Dirix LY, et al: Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat. 2004, 85: 13-22. 10.1023/B:BREA.0000021028.33926.a8.CrossRefPubMed
31.
Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R: Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer. 2004, 10: 6789-6795.CrossRef
32.
Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Roy F, van Beest P, Goovaerts G, Dirix LY, van Dam P, Fox SB, et al: Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer. 2003, 88: 718-725. 10.1038/sj.bjc.6600807.CrossRefPubMedPubMedCentral
33.
Van der Auwera I, Benoy I, Elst H, Van Laere S, Van Marck EA, Colpaert C, Van Dam P, Vermeulen PB, Dirix LY: Quantitative study of the angiogenic profile of inflammatory and non-inflammatory breast cancer using real-time RT-PCR [abstract]. Breast Cancer Res Treat. 2003, 82: s135-
34.
Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, Kallioniemi OP, Ethier SP: Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer. 1999, 81: 1328-1334. 10.1038/sj.bjc.6695007.CrossRefPubMedPubMedCentral
35.
van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD: A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res. 1999, 5: 2511-2519.PubMed
36.
Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH: A novel human xenograft model of inflammatory breast cancer. Cancer Res. 1999, 59: 5079-5084.PubMed
37.
Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, Sasaki H, Kasumi F, Yoshimoto M, Iwanaga T, et al: Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res. 2001, 61: 445-451.PubMed
38.
Tomlinson JS, Alpaugh ML, Barsky SH: An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 2001, 61: 5231-5241.PubMed
39.
Alpaugh ML, Tomlinson JS, Kasraeian S, Barsky SH: Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene. 2002, 21: 3631-3643. 10.1038/sj.onc.1205389.CrossRefPubMed
40.
Shirakawa K, Shibuya M, Heike Y, Takashima S, Watanabe I, Konishi F, Kasumi F, Goldman CK, Thomas KA, Bett A, et al: Tumor-infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer. Int J Cancer. 2002, 99: 344-351. 10.1002/ijc.10336.CrossRefPubMed
41.
Lerebours F, Bertheau P, Bieche I, Driouch K, De The H, Hacene K, Espie M, Marty M, Lidereau R: Evidence of chromosome regions and gene involvement in inflammatory breast cancer. Int J Cancer. 2002, 102: 618-622. 10.1002/ijc.10729.CrossRefPubMed
42.
Kleer CG, Zhang Y, Pan Q, van Golen KL, Wu ZF, Livant D, Merajver SD: WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene. 2002, 21: 3172-3180. 10.1038/sj.onc.1205462.CrossRefPubMed
43.
van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD: RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000, 60: 5832-5838.PubMed
44.
Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, Wu ZF, Merajver SD: WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res. 2004, 6: R110-R115. 10.1186/bcr755.CrossRefPubMed
45.
Jochum W, Passegue E, Wagner EF: AP-1 in mouse development and tumorigenesis. Oncogene. 2001, 20: 2401-2412. 10.1038/sj.onc.1204389.CrossRefPubMed
46.
Liauw SL, Benda RK, Morris CG, Mendenhall NP: Inflammatory breast carcinoma: outcomes with trimodality therapy for non-metastatic disease. Cancer. 2004, 100: 920-928. 10.1002/cncr.20083.CrossRefPubMed
47.
Thomas F, Arriagada R, Spielmann M, Mouriesse H, Le Chevalier T, Fontaine F, Tursz T: Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Cancer. 1995, 76: 2286-2290.CrossRefPubMed
48.
Chevallier B, Asselain B, Kunlin A, Veyret C, Bastit P, Graic Y: Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis. Cancer. 1987, 60: 897-902.CrossRefPubMed
49.
Rouesse J, Friedman S, Mouriesse H, Sarrazin D, Spielmann M: Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors. Breast Cancer Res Treat. 1990, 16: 15-22.CrossRefPubMed
50.
Sarrazin D, Rouesse J, Arriagada R, May-Levin F, Petit JY, Contesso G: Breast cancers in the evolutive phase. Rev Prat. 1978, 28: 999-1009.PubMed
51.
Lerebours F, Bertheau P, Bieche I, Plassa LF, Champeme MH, Hacene K, Toulas C, Espie M, Marty M, Lidereau R: Two prognostic groups of inflammatory breast cancer have distinct genotypes. Clin Cancer Res. 2003, 9: 4184-4189.PubMed
52.
Palangie T, Mosseri V, Mihura J, Campana F, Beuzeboc P, Dorval T, Garcia-Giralt E, Jouve M, Scholl S, Asselain B, et al: Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer. 1994, 7: 921-927. 10.1016/0959-8049(94)90115-5.CrossRef
53.
Levine PH, Steinhorn SC, Ries LG, Aron JL: Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst. 1985, 74: 291-297.PubMed
54.
Wilke D, Colwell B, Dewar R: Inflammatory breast carcinoma: comparison of survival of those diagnosed clinically, pathologically, or with both features. Am Surg. 1998, 64: 428-431.PubMed
55.
Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K, Wagstaff J, Pinedo HM: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer. 1998, 77: 621-626.CrossRefPubMedPubMedCentral
56.
Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999, 17: 460-469.CrossRefPubMed
57.
Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN: Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995, 4: 715-734.PubMed
58.
Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, et al: Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997, 40: 321-329. 10.1007/s002800050664.CrossRefPubMed
59.
Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P: Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993, 16: 223-228.CrossRefPubMed
60.
Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR: Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986, 46: 2578-2581.PubMed
61.
Harris EE, Schultz D, Bertsch H, Fox K, Glick J, Solin LJ: Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003, 55: 1200-1208. 10.1016/S0360-3016(02)04201-3.CrossRefPubMed
62.
Fields JN, Perez CA, Kuske RR, Fineberg BB, Bartlett N: Inflammatory carcinoma of the breast: treatment results on 107 patients. Int J Radiat Oncol Biol Phys. 1989, 17: 249-255.CrossRefPubMed
63.
Perez CA, Fields JN, Fracasso PM, Philpott G, Soares RL, Taylor ME, Lockett MA, Rush C: Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma. Cancer. 1994, 74: 466-476.CrossRefPubMed
64.
Villavicencio EH, Walterhouse DO, Iannaccone PM: The sonic hedgehog-patched-gli pathway in human development and disease. Am J Hum Genet. 2000, 67: 1047-1054.CrossRefPubMedPubMedCentral
65.
Oliver TG, Grasfeder LL, Carroll AL, Kaiser C, Gillingham CL, Lin SM, Wickramasinghe R, Scott MP, Wechsler-Reya RJ: Transcriptional profiling of the sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci USA. 2003, 100: 7331-7336. 10.1073/pnas.0832317100.CrossRefPubMedPubMedCentral
Metadata
Title
Update on inflammatory breast cancer
Authors
Florence Lerebours
Ivan Bieche
Rosette Lidereau
Publication date
01-04-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 2/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr997

Other articles of this Issue 2/2005

Breast Cancer Research 2/2005 Go to the issue

Commentary

The challenge of measuring circulating estradiol at low concentrations

Research article

Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case–control study

Commentary

Do breast implants after a mastectomy affect subsequent prognosis and survival?

Article selection

Articles selected in January 2005

Research article

Downregulation of the anaphase-promoting complex (APC)7 in invasive ductal carcinomas of the breast and its clinicopathologic relationships

Viewpoint

Show me the genes – I will tell you who/how to treat!
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits